SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 267 CNY | -1.09% |
|
+2.85% | +46.43% |
| Apr. 26 | Shenyang Xingqi Pharmaceutical's Q1 Profit Jumps 80% | MT |
| Apr. 25 | Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company's profit outlook over the next few years is a strong asset.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 74.16 times its estimated earnings per share for the ongoing year.
- The company appears highly valued given the size of its balance sheet.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +46.43% | 4.6B | - | ||
| +6.87% | 72.03B | A | ||
| -10.86% | 5.14B | A- | ||
| +5.38% | 3.96B | B- | ||
| -16.20% | 2.5B | C- | ||
| +21.43% | 2.43B | B | ||
| -26.20% | 2.32B | - | ||
| +19.92% | 2.18B | - | - | |
| +8.15% | 1.72B | D+ | ||
| -0.50% | 1.64B | - | - |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 300573 Stock
- Ratings Shenyang Xingqi Pharmaceutical Co.,Ltd.